APA (7th ed.) Citation

Boussahoua, M., Sutherland, C., Aponte Ribero, V., Enache, R., Le Lay, K., Le Dissez, C., & Chevalier, J. (2022). EE173 Cost-Effectiveness of Risdiplam for Patients with Types 1 - 3 Spinal Muscular Atrophy (SMA) in Francecost-Effectiveness of Risdiplam for Patients with Types 1 - 3 Spinal Muscular Atrophy (SMA) in France. Value in Health, 25(12), S87. https://doi.org/10.1016/j.jval.2022.09.423

Chicago Style (17th ed.) Citation

Boussahoua, M., CS Sutherland, V. Aponte Ribero, R. Enache, K. Le Lay, C. Le Dissez, and J. Chevalier. "EE173 Cost-Effectiveness of Risdiplam for Patients with Types 1 - 3 Spinal Muscular Atrophy (SMA) in Francecost-Effectiveness of Risdiplam for Patients with Types 1 - 3 Spinal Muscular Atrophy (SMA) in France." Value in Health 25, no. 12 (2022): S87. https://doi.org/10.1016/j.jval.2022.09.423.

MLA (9th ed.) Citation

Boussahoua, M., et al. "EE173 Cost-Effectiveness of Risdiplam for Patients with Types 1 - 3 Spinal Muscular Atrophy (SMA) in Francecost-Effectiveness of Risdiplam for Patients with Types 1 - 3 Spinal Muscular Atrophy (SMA) in France." Value in Health, vol. 25, no. 12, 2022, p. S87, https://doi.org/10.1016/j.jval.2022.09.423.